Abstract
To investigate the value of maintenance chemotherapy after early consolidation treatment, an attempt was made to induce remission in 162 previously untreated patients, age-range 7-65 years (median 43). The 74 patients who were still in remission after early consolidation treatment (given for 3-5 months) were assigned to either maintenance chemotherapy every 8 weeks for 2 years or to observation only. After a median observation period of 44 months there was no difference between the groups in duration of remission or survival. Surprisingly, patients above 40 survived longer after early consolidation (median 4 years) than did patients aged 40 and below (median 1.6 years, p = 0.0002).
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Agranulocytosis / chemically induced
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Marrow / drug effects
-
Child
-
Clinical Trials as Topic
-
Cytarabine / administration & dosage
-
Evaluation Studies as Topic
-
Female
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / mortality
-
Male
-
Middle Aged
-
Prednisone / administration & dosage
-
Prognosis
-
Random Allocation
-
Thioguanine / administration & dosage
-
Thrombocytopenia / chemically induced
-
Vincristine / administration & dosage
Substances
-
Cytarabine
-
Vincristine
-
Thioguanine
-
Prednisone